Approval history
The FDA approved Ozempic on December 5, 2017, to improve blood sugar control in adults with type 2 diabetes, along with diet and exercise. The approval was based on the SUSTAIN trial program.
In January 2020, the label added a lower risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes and established heart disease. A 2 mg weekly dose was added in 2022. On January 28, 2025, the FDA approved Ozempic to lower the risk of kidney decline, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial.
Medical uses
Ozempic contains semaglutide, a GLP-1 receptor agonist that helps the body release insulin when blood sugar is high and slows stomach emptying. It is approved only for adults with type 2 diabetes.
Ozempic is often linked with weight loss because semaglutide lowers appetite. The weight-loss version of the same molecule is sold as Wegovy, at higher doses and with its own label. Any use of Ozempic for weight alone is off-label.
Forms and doses
Ozempic injection comes in multi-dose pens and single-dose syringes, with weekly doses from 0.25 mg to 2 mg. As with other GLP-1 medicines, the label starts low and raises the dose in steps.
The name Ozempic is also used for a once-daily semaglutide tablet. The current (2026) tablet label lists Ozempic tablets in 1.5 mg, 4 mg and 9 mg strengths next to Rybelsus tablets, and states the two tablets are not interchangeable mg for mg.
Side effects and availability
The most common side effects of Ozempic are nausea, vomiting, diarrhea, stomach pain and constipation. The label has a boxed warning about thyroid C-cell tumors seen in rodent studies.
Ozempic is a prescription medicine. State-licensed pharmacies may also prepare compounded semaglutide for an individual prescription; compounded versions are not FDA-approved products. Our compounded semaglutide page compares programs that offer it.
Timeline
- December 5, 2017FDA approves Ozempic for type 2 diabetes.
- January 2020Cardiovascular risk reduction added for adults with type 2 diabetes and heart disease.
- 20222 mg weekly dose added.
- January 28, 2025Kidney indication approved, based on FLOW.
See also
References
- Ozempic (semaglutide) injection, original prescribing information, FDA 2017. accessdata.fda.gov
- Ozempic (semaglutide) injection, prescribing information, DailyMed 2026. dailymed.nlm.nih.gov
- Rybelsus and Ozempic (semaglutide) tablets, prescribing information, DailyMed 2026. dailymed.nlm.nih.gov
Last updated . Category: Medications. Browse all 38 WikiTelehealth entries.